MAM
ACAD icon

Marquette Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Marquette Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06K Sell
42
-29
-41% -$638 ﹤0.01% 717
2026
Q1 		$1.58K Buy
71
+49
+223% +$1.17K ﹤0.01% 599
2025
Q4 		$588 Buy
+22
New +$526 ﹤0.01% 620

Other funds holding ACAD

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Marquette Asset Management's ACAD Position: Q2 2026 in Review

Marquette Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 41% in Q2 2026, selling an estimated $638 and leaving 42 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Marquette Asset Management first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.58K in Q1 2026. 32 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Marquette Asset Management held 42 shares of Acadia Pharmaceuticals worth $1.06K as of Q2 2026.
  • Marquette Asset Management sold 29 Acadia Pharmaceuticals shares in Q2 2026, an estimated $638.
  • Acadia Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #717 holding.
  • Marquette Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Marquette Asset Management's Acadia Pharmaceuticals position peaked at $1.58K in Q1 2026.
  • 32 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.